Valuation UCB SA Wiener Boerse

Stocks

Real-time Estimate Tradegate 01:25:32 2026-09-11 EDT			5-day change	1st Jan Change
201.30 ^EUR	-3.27%		-6.13%	-12.34%

09-10	UCB: A rare window of affordability
09-09	UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,947	13,973	14,969	36,464	45,333	38,457	-	-
Change	-	-26.25%	7.12%	143.6%	24.32%	-15.17%	-	-
Enterprise Value (EV) ¹	19,807	15,973	17,146	37,918	45,326	38,762	36,649	34,090
Change	-	-19.36%	7.34%	121.15%	19.54%	-14.48%	-5.45%	-6.98%
P/E	17.9x	33.4x	44.8x	34.3x	29.1x	20.1x	16.6x	13.7x
PBR	2.32x	1.58x	1.67x	3.64x	4.18x	3.19x	2.78x	2.3x
PEG	-	-0.6x	-2.2x	0x	0.6x	0.9x	0.8x	0.6x
Capitalization / Revenue	3.28x	2.53x	2.85x	5.93x	5.86x	4.42x	3.97x	3.58x
EV / Revenue	3.43x	2.9x	3.26x	6.16x	5.86x	4.46x	3.79x	3.17x
EV / EBITDA	12.1x	12.7x	12.7x	25.7x	17.2x	12.7x	10.1x	7.99x
EV / EBIT	15x	23.7x	26.1x	45.4x	22.6x	15.8x	12.2x	9.34x
EV / FCF	15.6x	18.4x	38.5x	41.2x	24.6x	20.3x	13.9x	10.9x
FCF Yield	6.42%	5.43%	2.6%	2.43%	4.06%	4.93%	7.21%	9.15%
Dividend per Share ²	1.3	1.33	1.36	1.39	1.45	1.457	1.502	1.534
Rate of return	1.3%	1.81%	1.72%	0.72%	0.61%	0.72%	0.74%	0.76%
EPS ²	5.6	2.2	1.76	5.61	8.2	10.01	12.13	14.74
Distribution rate	23.2%	60.5%	77.3%	24.8%	17.7%	14.5%	12.4%	10.4%
Net sales ¹	5,777	5,517	5,252	6,152	7,741	8,695	9,677	10,751
EBITDA ¹	1,641	1,260	1,349	1,476	2,636	3,052	3,644	4,267
EBIT ¹	1,318	675	657	836	2,009	2,458	2,997	3,652
Net income ¹	1,058	418	343	1,065	1,558	1,931	2,325	2,816
Net Debt ¹	860	2,000	2,177	1,454	-7	305.5	-1,808	-4,367
Reference price ²	100.35	73.56	78.90	192.20	238.60	201.70	201.70	201.70
Nbr of stocks (in thousands)	188,812	189,959	189,721	189,720	189,996	190,663	-	-
Announcement Date	2/24/22	2/22/23	2/28/24	2/27/25	2/24/26	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
REGENERON PHARMACEUTICALS, INC.	18.7x	4.34x	10.2x	0.48%	79.21B
CSL LIMITED	20.24x	4.32x	13.42x	2.43%	58.22B
MODERNA, INC.	-16.13x	24.03x	-15.6x	-.--%	54.54B
SAMSUNG BIOLOGICS CO.,LTD.	35.37x	12.04x	23.09x	-.--%	48.89B
UCB	20.44x	4.52x	12.88x	0.71%	44.72B
BIOGEN INC.	36.39x	3.45x	13.17x	-.--%	31.83B
INCYTE CORPORATION	56.23x	3.59x	27.79x	-.--%	24.99B
INNOVENT BIOLOGICS, INC.	65.36x	6.91x	42.04x	-.--%	20.95B
SWEDISH ORPHAN BIOVITRUM AB	23.23x	4.99x	12.99x	-.--%	15.8B
Average	28.87x	7.58x	15.55x	0.4%	42.13B
Weighted average by Cap.	23.01x	8.23x	12.24x	0.56%